Bellevue Asset Management, LLC Blueprint Medicines Corp Transaction History

Bellevue Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$54.1 - $110.08 $757 - $1,541	-14 Closed	0 $0
Q4 2021 Feb 03, 2022	SELL	$94.25 - $115.99 $94 - $115	-1 Reduced 6.67%	14 $1,000
Q2 2021 Aug 09, 2021	SELL	$82.78 - $101.0 $165 - $202	-2 Reduced 11.76%	15 $1,000
Q1 2021 May 12, 2021	SELL	$90.71 - $108.28 $181 - $216	-2 Reduced 10.53%	17 $2,000
Q4 2020 Feb 11, 2021	SELL	$92.08 - $124.48 $276 - $373	-3 Reduced 13.64%	19 $2,000

Q2 2020 Jul 31, 2020	BUY	$57.09 - $79.27 $1,255 - $1,743	22 New	22 $2,000

8.58M

14.8K

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $7.73B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Bellevue Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bellevue Asset Management, LLC with notifications on news.